Sustained Response to Vemurafenib in a BRAF^V600E-Mutated Anaplastic Thyroid Carcinoma Patient

Thyroid. 2016 Oct;26(10):1515-1516. doi: 10.1089/thy.2015.0575. Epub 2016 Sep 27.

Authors

Gerald W Prager¹, Oskar Koperek², Marius E Mayerhoefer³, Leonhard Muellauer³, Fritz Wrba³, Bruno Niederle⁴, Christoph C Zielinski¹, Markus Raderer¹

Affiliations

¹ 1 Department of Medicine I, Comprehensive Cancer Center Vienna; Medical University of Vienna , Vienna, Austria .
² 2 Institute of Clinical Pathology; Medical University of Vienna , Vienna, Austria .
³ 3 Departments of Biomedical Imaging and Image-Guided Therapy; Medical University of Vienna , Vienna, Austria .
⁴ 4 Department of Endocrine Surgery; Medical University of Vienna , Vienna, Austria .

PMID: 27532222
DOI: 10.1089/thy.2015.0575

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Carcinoma / diagnostic imaging
Carcinoma / drug therapy*
Carcinoma / genetics*
Female
Humans
Indoles / therapeutic use*
Positron-Emission Tomography
Proto-Oncogene Proteins B-raf / genetics*
Sulfonamides / therapeutic use*
Thyroid Neoplasms / diagnostic imaging
Thyroid Neoplasms / drug therapy*
Thyroid Neoplasms / genetics*
Treatment Outcome
Vemurafenib

Substances

Antineoplastic Agents
Indoles
Sulfonamides
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf